Grifols, S.A. $GRFS Shares Sold by Anthracite Investment Company Inc.

Anthracite Investment Company Inc. decreased its holdings in shares of Grifols, S.A. (NASDAQ:GRFS) by 82.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,688 shares of the biotechnology company’s stock after selling 419,147 shares during the quarter. Anthracite Investment Company Inc.’s holdings in Grifols were worth $784,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GRFS. New York State Common Retirement Fund increased its stake in Grifols by 50.5% during the first quarter. New York State Common Retirement Fund now owns 2,452,728 shares of the biotechnology company’s stock worth $17,439,000 after acquiring an additional 823,456 shares during the last quarter. Groupe la Francaise acquired a new stake in shares of Grifols in the first quarter valued at $1,699,000. Highland Peak Capital LLC grew its stake in shares of Grifols by 24.1% in the first quarter. Highland Peak Capital LLC now owns 975,835 shares of the biotechnology company’s stock valued at $6,938,000 after buying an additional 189,625 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Grifols by 21.7% in the first quarter. Royal Bank of Canada now owns 486,824 shares of the biotechnology company’s stock valued at $3,461,000 after buying an additional 86,768 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Grifols by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock valued at $29,948,000 after buying an additional 80,507 shares in the last quarter.

Grifols Trading Down 0.9%

NASDAQ:GRFS opened at $9.46 on Friday. The firm has a market cap of $6.50 billion, a PE ratio of 45.05, a price-to-earnings-growth ratio of 0.32 and a beta of 0.69. The stock has a fifty day moving average price of $9.80 and a 200 day moving average price of $9.07. Grifols, S.A. has a 12-month low of $6.19 and a 12-month high of $11.14. The company has a current ratio of 2.64, a quick ratio of 0.95 and a debt-to-equity ratio of 1.20.

Grifols Announces Dividend

The firm also recently declared a special dividend, which was paid on Wednesday, August 20th. Shareholders of record on Tuesday, August 12th were paid a $0.1404 dividend. The ex-dividend date was Tuesday, August 12th. Grifols’s dividend payout ratio (DPR) is currently 66.67%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on GRFS shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Grifols in a research note on Saturday. Wall Street Zen cut Grifols from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 11th. Zacks Research raised Grifols to a “hold” rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Grifols in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $10.30.

Grifols Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.